Tag:
Joe Jimenez
Latest Headlines
Latest Headlines
Novartis CEO vowing to back ambitious $8B R&D strategy
While Pfizer goes about the business of dramatically reducing its R&D budget, Novartis CEO Joe Jimenez says he isn't about to go down that path. Instead, says the CEO, he intends to snip away at
Novartis chief eyes bolt-on deals up to $1B
Novartis ( $NVS ) CEO Joe Jimenez ( photo ) has a shopping list, and he's not afraid to share it. At the World Economic Forum in Davos, Jimenez chatted about his appetite for deals with the Wall Street
Jiminez: Novartis ($NVS) isn't 'giving up' on pharma model
Call it the Swiss strategy squabble. In advance of his first big public show since taking over Novartis ( $NVS ) as chief executive, Joe Jiminez ( photo ) talked strategy with the Financial Times--and
Has pharma outgrown the scientist CEO?
Is the era of the scientist-CEO over in Big Pharma? The Financial Times suggests it's so. And to hear the experts tell it, there's a reason for that. Executives with lots of commercial and marketing
Novartis CEO goes on a 'decluttering' drive
New Novartis ( NYSE:NVS ) chief Joe Jiminez ( photo ) is talking execution again. In an interview with the Financial Times, Jiminez described some of his initiatives--and they're all about the E word.
New Novartis chief talks productivity
Novartis has released more information about its U.S. drug reorganization: Andre Wyss is set to take the reins of that business, which is restructuring and cutting about 20 percent of its
Novartis eyes bolt-on deals in generics, vaccines
Now that it's done a $39.3 billion deal for Alcon, Novartis is joining the "no-megamerger" pharma fraternity. At the company's annual shareholders' meeting in Basel, Switzerland, new CEO Joe Jiminez
New Novartis chief scouting for 'bolt-on' buyouts
Newly-appointed Novartis CEO Joe Jimenez got his first chance to take the lead role at the annual shareholders' meeting today, and started to give the industry a better feel for just the kind of new
Vasella, Jimenez share the limelight
There's nothing like a surprise CEO announcement to get the media excited. Novartis CEO Daniel Vasella's ( photo ) confession that he'd be handing off his CEO responsibilities to pharma head Joe
Novartis chief steps aside for Jimenez
Look out, drugmakers: Another executive who spent his formative years outside the industry will take over at a Big Pharma near you. And much to the chagrin of the press, he's replacing one of the
